A novel study by Canadian physicians reported that the BioSTAR biodegradable implant achieved comparable closure rates to the Amplatzer Septal Occluder in children with atrial septal defect. A novel ...

A novel study by Canadian physicians reported that the BioSTARTM biodegradable implant achieved comparable closure rates to the Amplatzer Septal OccluderTM (ASO) in children with atrial septal defect ...

Rochester, MN - A new case series of patients with a previous stroke suggests that transcatheter device closure of patent foramen ovale (PFO) and atrial septal defect (ASD) is safe and eliminated ...

Rochester, MN - A case report of a patient who suffered erosion of an Amplatzer septal-occluder device (St Jude Medical) six years after it was implanted, resulting in cardiac tamponade and ...

Gore ASSURED Clinical Study results through 36 months demonstrate 100 percent closure success * with the GORE ® CARDIOFORM ASD Occluder, and consistent safety outcomes † across a broad range of ASD ...

Long-term survival after transcatheter closure of secundum atrial septal defects (ASD) is similar to that achieved after surgical closure, but the former method is far more likely to require ...

Three months of clopidogrel is sufficient to curb new-onset migraine headaches after percutaneous atrial septal defect (ASD) closure, new data from the randomized CANOA trial show. There was no ...

NEW YORK - March 12, 2019-The Cardiovascular Research Foundation (CRF) is pleased to announce that the latest issue of Structural Heart: The Journal of the Heart Team features original research ...

Patients undergoing transcatheter atrial septal defect (ASD) closure did not have worsening migraines after completing a course of dual antiplatelet therapy, the CANOA investigators found. Overall, ...